文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

醛固酮合酶抑制剂Lorundrostat治疗未控制高血压:Target-HTN随机临床试验

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项随机、安慰剂对照、剂量范围试验纳入200例服用2种及以上降压药仍未控制的高血压成人,初始队列163例血浆肾素受抑制且醛固酮升高,第二队列37例血浆肾素活性大于1.0 ng/mL/h。第8周时,50 mg每日一次组与安慰剂相比收缩压最小二乘均值差为-9.6 mm Hg(90% CI,-15.8至-3.4;P=0.01),100 mg每日一次组为-7.8 mm Hg(90% CI,-14.1至-1.5;P=0.04)。作者结论认为lorundrostat降低血压有效,但需进一步确证性研究。

要点

  • 在血浆肾素受抑制的未控制高血压患者中,lorundrostat 50 mg和100 mg每日一次组第8周收缩压较安慰剂显著降低。
  • 50 mg每日一次组与安慰剂收缩压最小二乘均值差为-9.6 mm Hg(90% CI,-15.8至-3.4;P=0.01)。
  • 6例受试者血清钾升高超过6.0 mmol/L,经减量或停药后纠正;未发生皮质醇功能不全。

核心结论

  • 在未控制高血压患者中,与安慰剂相比,lorundrostat降低血压有效,此结果将需要进一步的确证性研究。

研究设计与样本

  • 随机、安慰剂对照、剂量范围试验,纳入服用2种及以上降压药仍未控制高血压的成人。
  • 初始队列纳入163例血浆肾素受抑制(血浆肾素活性≤1.0 ng/mL/h)且血浆醛固酮升高(≥1.0 ng/dL)的受试者,随后纳入37例血浆肾素活性大于1.0 ng/mL/h的受试者。
  • 初始队列随机分配至安慰剂或lorundrostat 5个剂量之一(12.5 mg、50 mg或100 mg每日一次,或12.5 mg或25 mg每日两次);第二队列按1:6比例随机分配至安慰剂或lorundrostat 100 mg每日一次。
  • 主要终点为从基线至研究第8周自动化诊室收缩压的变化。
  • 2021年7月至2022年6月期间随机分配200例受试者,末次随访于2022年9月。

主要发现

  • 在血浆肾素受抑制的受试者中,治疗8周后,lorundrostat 100 mg每日一次、50 mg每日一次、12.5 mg每日一次和安慰剂组诊室收缩压变化分别为-14.1、-13.2、-6.9和-4.1 mm Hg。
  • 接受lorundrostat 25 mg每日两次和12.5 mg每日两次的受试者收缩压降幅分别为-10.1和-13.8 mm Hg。
  • 50 mg每日一次组与安慰剂收缩压最小二乘均值差为-9.6 mm Hg(90% CI,-15.8至-3.4;P=0.01)。
  • 100 mg每日一次组与安慰剂收缩压最小二乘均值差为-7.8 mm Hg(90% CI,-14.1至-1.5;P=0.04)。
  • 在血浆肾素未受抑制的受试者中,lorundrostat 100 mg每日一次使收缩压降低11.4 mm Hg(SD,2.5 mm Hg),与血浆肾素受抑制受试者接受相同剂量的血压降幅相似。

关键数值与推荐

  • 6例受试者血清钾升高超过6.0 mmol/L,经减量或停药后纠正。
  • 未发生皮质醇功能不全。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者结论指出该结果将需要进一步的确证性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Excess aldosterone production contributes to hypertension in both classical hyperaldosteronism and obesity-associated hypertension. Therapies that reduce aldosterone synthesis may lower blood pressure. OBJECTIVE: To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials. DESIGN, SETTING, AND PARTICIPANTS: Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications. An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h. INTERVENTIONS: Participants were randomized to placebo or 1 of 5 dosages of lorundrostat in the initial cohort (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily). In the second cohort, participants were randomized in a 1:6 ratio to placebo or lorundrostat, 100 mg once daily. MAIN OUTCOMES AND MEASURES: The primary end point was change in automated office systolic blood pressure from baseline to study week 8. RESULTS: Between July 2021 and June 2022, 200 participants were randomized, with final follow-up in September 2022. Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of -14.1, -13.2, -6.9, and -4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were -10.1 and -13.8 mm Hg, respectively. The least-squares mean difference between placebo and treatment in systolic blood pressure was -9.6 mm Hg (90% CI, -15.8 to -3.4 mm Hg; P = .01) for the 50-mg once-daily dose and -7.8 mm Hg (90% CI, -14.1 to -1.5 mm Hg; P = .04) for 100 mg daily. Among participants without suppressed PRA, 100 mg once daily of lorundrostat decreased systolic blood pressure by 11.4 mm Hg (SD, 2.5 mm Hg), which was similar to blood pressure reduction among participants with suppressed PRA receiving the same dose. Six participants had increases in serum potassium above 6.0 mmol/L that corrected with dose reduction or drug discontinuation. No instances of cortisol insufficiency occurred. CONCLUSIONS AND RELEVANCE: Among individuals with uncontrolled hypertension, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05001945.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Laffin LJ, Rodman D, Luther JM, et al. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA. 2023. PMID: 37690061. doi:10.1001/jama.2023.16029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。